Protara Therapeutics (TARA) Total Non-Current Liabilities (2015 - 2016)

Protara Therapeutics (TARA) recorded quarterly Total Non-Current Liabilities of $4.8 million in Q3 2016, up 7.72% quarter-over-quarter from $4.5 million in Q2 2016, and up 52.9% on a YoY basis from $3.2 million in Q4 2015.

Protara Therapeutics (TARA) Total Non-Current Liabilities (2015 - 2016) Analysis & Trends

Protara Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $4.8 million for Q3 2016.

  • In Q3 2016, Total Non-Current Liabilities rose 52.9% year-over-year to $4.8 million; the TTM figure through Sep 2016 stood at $4.8 million (up 52.9% YoY), while the FY2015 annual figure was $3.6 million, changed N/A from the prior year.
  • Total Non-Current Liabilities was $4.8 million for Q3 2016 at Protara Therapeutics, up from $4.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.8 million in Q3 2016 to a low of $2.8 million in Q2 2015.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - 42,980.09
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 11.03 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - 644,700.00
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.71 Bn 91.71 Bn - 64.76 Mn
10 Protara Therapeutics 216.35 Mn 216.35 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2016 4.84 Mn
Jun 30, 2016 4.50 Mn
Mar 31, 2016 3.27 Mn
Dec 31, 2015 3.60 Mn
Sep 30, 2015 3.17 Mn
Jun 30, 2015 2.77 Mn